This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Athersys Announces Completion Of Patient Enrollment For Single Dose Arm Of Phase I Study Of MultiStem(R) For Hematopoietic Stem Cell Transplant Support

CLEVELAND, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem ® to patients being treated for leukemia or other blood born cancers. The study involves administration of a single or multiple doses of MultiStem, an allogeneic cell therapy product, to patients following radiation therapy and a donor derived hematopoietic stem cell transplant. Patients receiving such transplants are typically at risk for Graft-Versus-Host Disease (GVHD), as well as other complications, such as tissue damage from the radiation and chemotherapy treatments that are conducted prior to the transplant. Initial results of safety information from the single dose arm of this trial are expected to be announced following the completion of patient evaluation periods and subsequent analysis of data. 

GVHD is one of the major limitations of allogeneic donor derived hematopoietic stem cell transplants. This complication is a significant cause of morbidity and mortality and is thought to be initiated by activation of donor immune cells, such as activated T-cells, that attack host cells in the transplant recipient as foreign tissue. Acute GVHD is associated with damage to the liver, skin, gastrointestinal tract and other tissues. Moderate to severe GVHD Grades II-IV occurs in 30-50% of matched related hematopoietic stem cell transplants (HSCT) and 50-70% of matched unrelated donor recipients. Severe GVHD requires treatment using intense immunosuppression with steroids and additional agents, and patients may develop severe infections as a result of such immunosuppression. An agent or cell therapy that could prevent the incidence and/or severity of GVHD without increasing relapse or infectious risk in HSCT patients would provide substantial benefits.

"Despite significant advances in recent years, treatment of leukemia and other cancers of the blood and immune system is a substantial clinical challenge. Radiation and chemotherapy followed by hematopoietic stem cell transplantation remains the standard of care in many areas. Unfortunately, many patients experience complications from treatment, such as GVHD, that can be debilitating or life threatening," commented Dr. Robert Deans, Senior Vice President of Regenerative Medicine of Athersys. "Based on results from preclinical studies conducted in coordination with independent labs, we believe that MultiStem has the potential to reduce the incidence and severity of GVHD and other complications and improve patient outcomes. This Phase I safety study represents an important step in the development of MultiStem for this condition, and we look forward to evaluating the data from the trial upon completion of the appropriate follow up visits."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs